相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice
Sebastian Steven et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Targeting vascular (endothelial) dysfunction
Andreas Daiber et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress
Yanna Lei et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials
Stephen L. Atkin et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy
Ahmed A. Hasan et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2017)
Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis
Takahiro Uchida et al.
RENAL FAILURE (2017)
Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice
Hotimah Masdan Salim et al.
VASCULAR PHARMACOLOGY (2017)
Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
Maimaiti Yisireyili et al.
SCIENTIFIC REPORTS (2017)
Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice
Annayya R. Aroor et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial
Yuichi J. Shimada et al.
AMERICAN HEART JOURNAL (2016)
The contributions of dipeptidyl peptidase IV to inflammation in heart failure
Thiago de Almeida Salles et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2016)
Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats
Masako Uchii et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release
Tania Romacho et al.
JOURNAL OF HYPERTENSION (2016)
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Young-Sun Lee et al.
MEDIATORS OF INFLAMMATION (2016)
Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits
Tsutomu Hirano et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors
Marko Anderluh et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model
Maimaiti Yisireyili et al.
PSYCHONEUROENDOCRINOLOGY (2016)
Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice
Hotimah Masdan Salim et al.
VASCULAR PHARMACOLOGY (2016)
Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study
Young-Gun Kim et al.
JOURNAL OF DIABETES RESEARCH (2016)
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
Sung-Ho Kim et al.
DIABETES & METABOLISM JOURNAL (2016)
Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
Gwon-Soo Jung et al.
DIABETES & METABOLISM JOURNAL (2016)
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes
Ju-Young Moon et al.
PLOS ONE (2016)
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
Sen Shi et al.
FIBROGENESIS & TISSUE REPAIR (2016)
Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
Yochai Birnbaum et al.
BMJ OPEN DIABETES RESEARCH & CARE (2016)
An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury
Madoka Ihara et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia
Sebastian Steven et al.
BASIC RESEARCH IN CARDIOLOGY (2015)
A new combination of sitagliptin and furosemide protects against remote myocardial injury induced by renal ischemia/reperfusion in rats
Mahmoud I. Youssef et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
Enrique Z. Fisman et al.
CARDIOVASCULAR DIABETOLOGY (2015)
An Overview of Recent Dipeptidyl Peptidase-IV Inhibitors: Linking their Structure and Physico-Chemical Properties with SAR, Pharmacokinetics and Toxicity
Andrija Smelcerovic et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2015)
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy
Eunsoo Jung et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function
Quan Gong et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis
Gianluigi Savarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease
Sebastian Steven et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions
Yukihisa S. Watanabe et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2015)
Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats
Yu-Sheng Liu et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2015)
The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms
Hwan-Jin Hwang et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation
Seung Hee Choi et al.
VASCULAR PHARMACOLOGY (2015)
DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats
Md. Ashraful Alam et al.
DIABETOLOGY & METABOLIC SYNDROME (2015)
Dipeptidyl-Peptidase-4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low-Density Lipoprotein (LDL) Receptor- Deficient Mice
Koji Akita et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Pituitary Adenylate Cyclase-Activating Polypeptide Protects Glomerular Podocytes from Inflammatory Injuries
Kenichi Sakamoto et al.
JOURNAL OF DIABETES RESEARCH (2015)
Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts
Tsung-Ming Lee et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
A DPP-4 Inhibitor Suppresses Fibrosis and Inflammation on Experimental Autoimmune Myocarditis in Mice
Hiroyuki Hirakawa et al.
PLOS ONE (2015)
Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury
Yoshiki Higashijima et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Annayya R. Aroor et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2014)
Uncoupling Protein-2 Mediates DPP-4 Inhibitor-Induced Restoration of Endothelial Function in Hypertension Through Reducing Oxidative Stress
Limei Liu et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2
Nina Wronkowitz et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2014)
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Yuichi Terawaki et al.
CARDIOVASCULAR DIABETOLOGY (2014)
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms
Yanmei Zeng et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Angelo Avogaro et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
Keizo Kanasaki et al.
DIABETES (2014)
Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart
Kroekkiat Chinda et al.
DIABETES & VASCULAR DISEASE RESEARCH (2014)
The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
Angelo Avogaro et al.
DIABETES CARE (2014)
Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors
Bhumika D. Patel et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes
Yuya Nakamura et al.
HEMODIALYSIS INTERNATIONAL (2014)
Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis
S. Nakashima et al.
HORMONE AND METABOLIC RESEARCH (2014)
The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Protects against Dyslipidemia-Related Kidney Injury in Apolipoprotein E Knockout Mice
Jingjing Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?
Lucienne Juillerat-Jeanneret
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats
Shinji Takai et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2014)
Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats
Wulan Bao et al.
JOURNAL OF VASCULAR SURGERY (2014)
Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes
Hwan-Jin Hwang et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
MicroRNA-29b Inhibits Diabetic Nephropathy in db/db Mice
Hai-Yong Chen et al.
MOLECULAR THERAPY (2014)
Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
Catarina Marques et al.
MEDIATORS OF INFLAMMATION (2014)
Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes
Andre J. Tremblay et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
Na-Hyung Kim et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach
Yao Dai et al.
ACTA DIABETOLOGICA (2013)
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
Jixin Zhong et al.
ATHEROSCLEROSIS (2013)
Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond
Gian Paolo Fadini et al.
ATHEROSCLEROSIS (2013)
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
Mika Nabeno et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats
Nattayaporn Apaijai et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Samuel S. Engel et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
Yuji Ishibashi et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials
Maximilian von Eynatten et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials
Pitchai Balakumar et al.
CELLULAR SIGNALLING (2013)
Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Improves Endothelial Dysfunction in Association With Its Anti-Inflammatory Effects in Patients With Coronary Artery Disease and Uncontrolled Diabetes
Junichi Matsubara et al.
CIRCULATION JOURNAL (2013)
Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease
Usha Panchapakesan et al.
CLINICAL SCIENCE (2013)
A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation
Jixin Zhong et al.
DIABETES (2013)
Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
Koji Sakata et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2013)
Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice
Nasib Ervinna et al.
ENDOCRINOLOGY (2013)
Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: Role of GLP-1 and GLP-1 receptor
Dalia M. Abd El Motteleb et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model
Guanglei Chang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes
T-I Lee et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction
Yen-Ta Chen et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients
Noriko Satoh-Asahara et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms
Belen Picatoste et al.
PLOS ONE (2013)
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
Kwon Wook Joo et al.
BMC NEPHROLOGY (2013)
DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes
Annayya Aroor et al.
CARDIORENAL MEDICINE (2013)
Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
B. Solun et al.
CURRENT CARDIOLOGY REPORTS (2013)
Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors
Steven G. Chrysant et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Fused bicyclic heteroarylpiperazine- substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group
Tomohiro Yoshida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Tomohiro Yoshida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Michael E. Cobble et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
Odd Erik Johansen et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition
Swenja Kroeller-Schoen et al.
CARDIOVASCULAR RESEARCH (2012)
Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes Role of dipeptidyl peptidase-IV inhibition
Maria Rosaria Rizzo et al.
DIABETES CARE (2012)
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe -/- mice
F. Vittone et al.
DIABETOLOGIA (2012)
Cardioprotective Effects of Metformin and Vildagliptin in Adult Rats with Insulin Resistance Induced by a High-Fat Diet
Nattayaporn Apaijai et al.
ENDOCRINOLOGY (2012)
Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
Nelson Gomez et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats
R. Preston Mason et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2012)
Sitagliptin Exerts an Antinflammatory Action
Antoine Makdissi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Deficient Mice
Junichi Matsubara et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy
Markus L. Alter et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Renal and Cardiac Effects of DPP-4 Inhibitors - from Preclinical Development to Clinical Research
Berthold Hocher et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Erratum to: GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells
Yunshan Hu et al.
MOLECULAR BIOLOGY REPORTS (2012)
Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
Soo Lim et al.
PLOS ONE (2012)
Identification of Novel Human Dipeptidyl Peptidase-IV Inhibitors of Natural Origin (Part I): Virtual Screening and Activity Assays
Laura Guasch et al.
PLOS ONE (2012)
DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury
Lorenzo L. F. Glorie et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2012)
Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats
Wei Jing Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
Zubair Shah et al.
CIRCULATION (2011)
Sitagliptin reduces albuminuria in patients with type 2 diabetes
Sachiko Hattori
ENDOCRINE JOURNAL (2011)
Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
Cristina Mega et al.
EXPERIMENTAL DIABETES RESEARCH (2011)
Sitagliptin Augments Protective Effects of GLP-1 against Advanced Glycation End Product Receptor Axis in Endothelial Cells
Y. Ishibashi et al.
HORMONE AND METABOLIC RESEARCH (2011)
DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice
Nga N. Ta et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis
Takanori Matsui et al.
PHARMACOLOGICAL RESEARCH (2011)
Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes
Jitendra Vaghasiya et al.
REGULATORY PEPTIDES (2011)
Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways
Zubair Shah et al.
VASCULAR PHARMACOLOGY (2011)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
Yumei Ye et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
Liliana Ferreira et al.
MEDIATORS OF INFLAMMATION (2010)
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Peter R. Flatt et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
Matthias Eckhardt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
H Ikushima et al.
CELLULAR IMMUNOLOGY (2002)
CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes
MD Gorrell et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2001)
分享论文
